Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma.
Lung cancer
Peripheral blood
Plasmacytoïd dendritic cells
Prognosis
Tumor-specific T cell responses
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
10
01
2022
accepted:
28
07
2022
pubmed:
22
8
2022
medline:
25
2
2023
entrez:
21
8
2022
Statut:
ppublish
Résumé
Plasmacytoid dendritic cells (pDCs) represent a subset of antigen-presenting cells that play an ambivalent role in cancer immunity. Here, we investigated the clinical significance of circulating pDCs and their interaction with tumor-specific T cell responses in patients with non-small cell lung cancer (NSCLC, n = 126) . The relation between intratumoral pDC signature and immune checkpoint inhibitors efficacy was also evaluated. Patients with NSCLC had low level but activated phenotype pDC compared to healthy donors. In overall population, patients with high level of pDC (pDC
Identifiants
pubmed: 35989364
doi: 10.1007/s00262-022-03271-9
pii: 10.1007/s00262-022-03271-9
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-589Subventions
Organisme : Institut National Du Cancer
ID : INCa-PLBio-2018
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Hiam-Galvez KJ, Allen BM, Spitzer MH (2021) Systemic immunity in cancer. Nat Rev Cancer 21:345–359
pubmed: 33837297
pmcid: 8034277
doi: 10.1038/s41568-021-00347-z
Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM et al (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168:487-502.e15
pubmed: 28111070
pmcid: 5312823
doi: 10.1016/j.cell.2016.12.022
Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC et al (2019) Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell 177:556-571.e16
pubmed: 30955881
pmcid: 6954108
doi: 10.1016/j.cell.2019.02.005
Cancel J-C, Crozat K, Dalod M, Mattiuz R (2019) Are conventional type 1 dendritic cells critical for protective antitumor immunity and how? Front Immunol 10:9
pubmed: 30809220
pmcid: 6379659
doi: 10.3389/fimmu.2019.00009
Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J et al (2017) Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356:eaah4573
pubmed: 28428369
pmcid: 5775029
doi: 10.1126/science.aah4573
Lande R, Gilliet M (2010) Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 1183:89–103
pubmed: 20146710
doi: 10.1111/j.1749-6632.2009.05152.x
Swiecki M, Colonna M (2015) The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 15:471–485
pubmed: 26160613
pmcid: 4808588
doi: 10.1038/nri3865
Tel J, Aarntzen EHJG, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D et al (2013) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 73:1063–1075
pubmed: 23345163
doi: 10.1158/0008-5472.CAN-12-2583
Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A et al (2019) The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer 7:109
pubmed: 30999964
pmcid: 6471787
doi: 10.1186/s40425-019-0580-6
Mitchell D, Chintala S, Dey M (2018) Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol 322:63–73
pubmed: 30049538
doi: 10.1016/j.jneuroim.2018.06.012
Conrad C, Gregorio J, Wang Y-H, Ito T, Meller S, Hanabuchi S et al (2012) Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 72:5240–5249
pubmed: 22850422
pmcid: 3652570
doi: 10.1158/0008-5472.CAN-12-2271
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20:7–24
pubmed: 31467405
doi: 10.1038/s41577-019-0210-z
Nam J-H, Lee J-H, Choi S-Y, Jung N-C, Song J-Y, Seo H-G et al (2021) Functional ambivalence of dendritic cells: tolerogenicity and immunogenicity. Int J Mol Sci 22:4430
pubmed: 33922658
pmcid: 8122871
doi: 10.3390/ijms22094430
Kini Bailur J, Gueckel B, Pawelec G (2016) Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. J Transl Med 14:151
pubmed: 27234566
pmcid: 4884426
doi: 10.1186/s12967-016-0905-x
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C et al (2015) Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med 13:9
pubmed: 25592374
pmcid: 4326397
doi: 10.1186/s12967-014-0376-x
Lee YS, Radford KJ (2019) Chapter three—the role of dendritic cells in cancer. In: Lhuillier C, Galluzzi L (eds) Immunobiology of dendritic cells part A. Academic Press, New York, pp 123–178
doi: 10.1016/bs.ircmb.2019.07.006
Sosa Cuevas E, Ouaguia L, Mouret S, Charles J, De Fraipont F, Manches O et al (2020) BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clin Transl Immunol 9:e1190
doi: 10.1002/cti2.1190
Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E et al (2019) Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. Br J Cancer 121:405–416
pubmed: 31358938
pmcid: 6738094
doi: 10.1038/s41416-019-0531-5
Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A et al (2021) Naturally occurring telomerase-specific CD4 T-cell immunity in melanoma. J Investig Dermatol 142:435–444
pubmed: 34352265
doi: 10.1016/j.jid.2021.07.160
Kim S, François E, André T, Samalin E, Jary M, El Hajbi F et al (2018) Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 19:1094–1106
pubmed: 30042063
doi: 10.1016/S1470-2045(18)30321-8
Safi S, Yamauchi Y, Rathinasamy A, Stamova S, Eichhorn M, Warth A et al (2017) Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. Oncoimmunology 6:e1360458
pubmed: 29147626
pmcid: 5674973
doi: 10.1080/2162402X.2017.1360458
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH et al (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619–628
pubmed: 12208877
pmcid: 2193999
doi: 10.1084/jem.20012142
Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung C-F et al (2007) HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res Off J Am Assoc Cancer Res 13:2479–2487
doi: 10.1158/1078-0432.CCR-06-2916
Dhodapkar KM, Gettinger SN, Das R, Zebroski H, Dhodapkar MV (2013) SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology 2:e25205
pubmed: 24073380
pmcid: 3782159
doi: 10.4161/onci.25205
Janssen N, Fortis SP, Speigl L, Haritos C, Sotiriadou NN, Sofopoulos M et al (2017) Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients. Breast Cancer Res Treat 161:51–62
pubmed: 27787640
doi: 10.1007/s10549-016-4037-z
Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P et al (2012) Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res Off J Am Assoc Cancer Res 18:2943–2953
pubmed: 22407833
doi: 10.1158/1078-0432.CCR-11-3185
Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C et al (2016) Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients. Oncoimmunology 5:e1137416
pubmed: 27467955
pmcid: 4910811
doi: 10.1080/2162402X.2015.1137416
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M et al (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother CII 59:1489–1501
pubmed: 20549207
doi: 10.1007/s00262-010-0875-4
Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R et al (2022) MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. J Immunother Cancer 10:e004241
pubmed: 35277462
pmcid: 8919440
doi: 10.1136/jitc-2021-004241
Poropatich K, Dominguez D, Chan W-C, Andrade J, Zha Y, Wray B et al (2020) OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. J Clin Investig 130:3528–3542
pubmed: 32182225
pmcid: 7324178
doi: 10.1172/JCI131992
Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835–1837
pubmed: 10364556
doi: 10.1126/science.284.5421.1835
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
pubmed: 30207593
doi: 10.3322/caac.21492
Failli A, Legitimo A, Orsini G, Romanini A, Consolini R (2013) Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma. Cancer Lett 337:184–192
pubmed: 23684927
doi: 10.1016/j.canlet.2013.05.013
Lauret Marie Joseph E, Laheurte C, Jary M, Boullerot L, Asgarov K, Gravelin E et al (2020) Immunoregulation and clinical implications of ANGPT2/TIE2+ M-MDSC signature in non-small cell lung cancer. Cancer Immunol Res 8:268–279
pubmed: 31871121
doi: 10.1158/2326-6066.CIR-19-0326
Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R et al (2010) Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Investig Dermatol 130:1646–1656
pubmed: 20220766
doi: 10.1038/jid.2010.24
Lenahan C, Avigan D (2006) Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res BCR 8:101
pubmed: 16469120
doi: 10.1186/bcr1375
Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G et al (2004) Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res Off J Am Assoc Cancer Res 10:7260–7269
pubmed: 15534100
doi: 10.1158/1078-0432.CCR-04-0872
Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL et al (2003) Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 33:1052–1062
pubmed: 12672071
doi: 10.1002/eji.200323676
Gardner A, Ruffell B (2016) Dendritic cells and cancer immunity. Trends Immunol 37:855–865
pubmed: 27793569
pmcid: 5135568
doi: 10.1016/j.it.2016.09.006
Kadowaki N, Antonenko S, Lau JY, Liu YJ (2000) Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192:219–226
pubmed: 10899908
pmcid: 2193254
doi: 10.1084/jem.192.2.219
Noubade R, Majri-Morrison S, Tarbell KV (2019) Beyond cDC1: emerging roles of DC crosstalk in cancer immunity. Front Immunol 10:1014
pubmed: 31143179
pmcid: 6521804
doi: 10.3389/fimmu.2019.01014
Faith A, Peek E, McDonald J, Urry Z, Richards DF, Tan C et al (2007) Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am J Respir Cell Mol Biol 36:360–367
pubmed: 17023687
doi: 10.1165/rcmb.2006-0284OC
Mathan TSMM, Figdor CG, Buschow SI (2013) Human plasmacytoid dendritic cells: from molecules to intercellular communication network. Front Immunol 4:372
pubmed: 24282405
pmcid: 3825182
doi: 10.3389/fimmu.2013.00372
Marciscano AE, Anandasabapathy N (2021) The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol 52:101481
pubmed: 34023170
pmcid: 8545750
doi: 10.1016/j.smim.2021.101481
Zhang S, Chopin M, Nutt SL (2021) Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy. Trends Immunol 42:1113–1127
pubmed: 34728143
doi: 10.1016/j.it.2021.10.004
Eisenbarth SC (2019) Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol 19:89–103
pubmed: 30464294
pmcid: 7755085
doi: 10.1038/s41577-018-0088-1
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E et al (2020) Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med 12:eaav7431
pubmed: 32161104
doi: 10.1126/scitranslmed.aav7431
Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Kalinski P et al (2020) Plasmacytoid dendritic cell (pDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) more strongly than conventional dendritic cell (cDC). Cancers 12:E3342
doi: 10.3390/cancers12113342
Kießler M, Plesca I, Sommer U, Wehner R, Wilczkowski F, Müller L et al (2021) Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J Immunother Cancer 9:e001813
pubmed: 33762320
pmcid: 7993360
doi: 10.1136/jitc-2020-001813